Changeflow GovPing Pharma & Drug Safety Buprenorphine Depot Formulation Controlled-Rele...
Routine Notice Added Final

Buprenorphine Depot Formulation Controlled-Release Matrix

Favicon for changeflow.com USPTO Patent Applications - Pharma (A61K)
Published
Detected
Email

Summary

USPTO published patent application US20260097031A1 for a depot precursor formulation comprising a controlled-release matrix with an oxygen-containing organic solvent and at least 12% by weight buprenorphine or salts thereof. Inventors include Fredrik Tiberg, Ian Harwigsson, and Markus Johnsson. The application covers methods for pain management and opioid maintenance treatment.

What changed

USPTO published patent application US20260097031A1 for a depot precursor formulation comprising a controlled-release matrix, an oxygen-containing organic solvent, and at least 12% by weight buprenorphine or salts thereof. The formulation is designed for pain management and opioid maintenance treatment. Filing date was May 20, 2025, with application number 19213277.

For pharmaceutical manufacturers developing controlled-release opioid formulations, this patent application represents potential intellectual property that may affect freedom-to-operate considerations for similar depot formulations. Parties should monitor the prosecution history for claim scope and any issued claims that may create licensing obligations or design-around requirements.

What to do next

  1. Monitor for patent grant or office action

Archived snapshot

Apr 12, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← USPTO Patent Applications

OPIOID FORMULATIONS

Application US20260097031A1 Kind: A1 Apr 09, 2026

Inventors

Fredrik Tiberg, Ian Harwigsson, Markus Johnsson

Abstract

A depot precursor formulation comprising: a) a controlled-release matrix; b) at least oxygen containing organic solvent; c) at least 1 2% by weigh of at least one active agent selected from buprenorphine and salts thereof, calculated as buprenorphine free base. Corresponding depot compositions and methods of treatment in pain management, by opioid maintenance and related methods are provided.

CPC Classifications

A61K 31/4748 A61K 9/0024 A61K 31/485 A61K 47/10 A61K 47/14 A61K 47/24 A61K 47/34

Filing Date

2025-05-20

Application No.

19213277

View original document →

Get daily alerts for USPTO Patent Applications - Pharma (A61K)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from USPTO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
USPTO
Published
April 9th, 2026
Instrument
Notice
Legal weight
Binding
Stage
Final
Change scope
Minor
Document ID
US20260097031A1

Who this affects

Applies to
Pharmaceutical companies Drug manufacturers
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Patent application Controlled-release formulation Opioid drug delivery
Geographic scope
United States US

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Pharmaceuticals Healthcare

Get alerts for this source

We'll email you when USPTO Patent Applications - Pharma (A61K) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!